Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Oct 3, 2013
Karyopharm Therapeutics Announces Appointment of Garen Bohlin to Board of DirectorsNatick, Mass. – October 3, 2013 – Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company...
-
Aug 7, 2013
Karyopharm Therapeutics Announces Preclinical Data for Selinexor (KPT-330) in Acute Myeloblastic Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Models at FASEB Science Research...
-
Jul 31, 2013Karyopharm Therapeutics Secures $19 Million in Series B Financing Extension
Natick, Mass. – July 31, 2013 – Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing first-in-class nuclear transport modulators for the treatment of...
-
Jun 2, 2013
Karyopharm Therapeutics Presents Clinical Data for Selinexor (KPT-330), a First-in-Class Selective Inhibitor of Nuclear Export (SINE), in Solid Tumors at the 2013 ASCO Annual MeetingNatick, Mass....
-
May 28, 2013
Karyopharm Therapeutics to Present New Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 EHA CongressNatick, Mass. – May 28, 2013 – Karyopharm Therapeutics Inc., a leader...